← back to search

Tiffany W. Chow

University of California, Irvine · US
Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Amyotrophic Lateral Sclerosis Research, and Neurobiology of Language and Bilingualism.
h-index
41
citations
11,304
works
156
NIH funding
primary concept
email

Recent publications

Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
Neurology 2025cited by 2position: middledoi
Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment
JAMA Psychiatry 2024cited by 28position: middledoi
Asian Cohort for Alzheimer's Disease (ACAD) pilot study on genetic and non‐genetic risk factors for Alzheimer's disease among Asian Americans and Canadians
Alzheimer s & Dementia 2024cited by 20position: middledoi
Using community-based geographical information system (GIS) to recruit older Asian Americans in an Alzheimer’s disease study
BMJ Open 2023cited by 8position: middledoi
The Asian Cohort for Alzheimer’s Disease (ACAD) Pilot Study
Alzheimer s & Dementia 2022cited by 1position: lastdoi
The Asian Cohort for Alzheimer’s Disease (ACAD) study
Alzheimer s & Dementia 2021cited by 0position: middledoi
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia
JAMA Neurology 2020cited by 363position: middledoi
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease
JAMA Neurology 2019cited by 139position: middledoi
Amyloid deposition in semantic dementia: a positron emission tomography study
International Journal of Geriatric Psychiatry 2016cited by 9position: lastdoi
Cluster M Mycobacteriophages Bongo, PegLeg, and Rey with Unusually Large Repertoires of tRNA Isotypes
Journal of Virology 2013cited by 47position: middledoi
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
Alzheimer s & Dementia 2012cited by 76position: middledoi
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Alzheimer s & Dementia 2012cited by 55position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Haeok Lee · University of Washington2 papers (2021–2023)Rema Raman · ADS Group2 papers (2019–2020)James B. Brewer · University of California San Diego2 papers (2019–2020)Devon Gessert · University of California San Diego2 papers (2019–2020)Van Ta Park · University of Southern California2 papers (2021–2023)Robert A. Rissman · University of Southern California2 papers (2019–2020)Michael S. Rafii · University of Southern California2 papers (2019–2020)Michael Donohue · University of Southern California2 papers (2019–2020)Gyungah Jun · Boston University2 papers (2021–2023)Li‐San Wang · NewYork–Presbyterian Hospital1 papers (2023–2023)Kelly Harless · University of Southern California1 papers (2020–2020)Jeffrey Kaye · University of Southern California1 papers (2019–2019)Howard Feldman · University of San Diego1 papers (2021–2021)Isabelle Le Ber · Centre National de la Recherche Scientifique1 papers (2025–2025)Ariel Graff‐Guerrero · Centre for Addiction and Mental Health1 papers (2016–2016)Guerry M. Peavy · University of California San Diego1 papers (2021–2021)Chung‐Kai Sun · National Yang Ming Chiao Tung University1 papers (2020–2020)Yun‐Beom Choi · Columbia University1 papers (2023–2023) · 1 papers (2023–2023)Rohit Varma · University of Southern California1 papers (2021–2021)